Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Gewählte Publikation:

Open Access Logo

Publikationstyp: Zeitschriftenaufsatz
Dokumenttyp: Originalarbeit

Jahr: 2018

AutorInnen: Gabner, S; Ertl, R; Velde, K; Renner, M; Jenner, F; Egerbacher, M; Hlavaty, J

Titel: Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment.

Quelle: J Gene Med. 2018; 20(5):e3021



Autor/innen der Vetmeduni Vienna:

Egerbacher Monika
Ertl Reinhard
Gabner Simone
Hlavaty Juraj
Jenner Florien
Velde Karsten

Beteiligte Vetmed-Organisationseinheiten
Institut für Pathologie
Universitätsklinik für Pferde, Klinische Abteilung für Pferdechirurgie
VetCore


Zugehörige(s) Projekt(e): Inducible expression of IL-1 receptor antagonist protein in equine mesenchymal stem cells


Abstract:
A combination of tissue engineering methods employing mesenchymal stem cells (MSCs) together with gene transfer takes advantage of innovative strategies and highlights a new approach for targeting osteoarthritis (OA) and other cartilage defects. Furthermore, the development of systems allowing tunable transgene expression as regulated by natural disease-induced substances is highly desirable.Bone marrow-derived equine MSCs were transduced with a lentiviral vector expressing interleukin-1 receptor antagonist (IL-1Ra) gene under the control of an inducible nuclear factor-kappa B-responsive promoter and IL-1Ra production upon pro-inflammatory cytokine stimulation [tumor necrosis factor (TNF)α, interleukin (IL)-1β] was analysed. To assess the biological activity of the IL-1Ra protein that was produced and the therapeutic effect of IL-1Ra-expressing MSCs (MSC/IL-1Ra), cytokine-based two- and three-dimensional in vitro models of osteoarthritis using equine chondrocytes were established and quantitative real-time polymerase chain reaction (PCR) analysis was used to measure the gene expression of aggrecan, collagen IIA1, interleukin-1β, interleukin-6, interleukin-8, matrix metalloproteinase-1 and matrix metalloproteinase-13.A dose-dependent increase in IL-1Ra expression was found in MSC/IL-1Ra cells upon TNFα administration, whereas stimulation using IL-1β did not lead to IL-1Ra production above the basal level observed in nonstimulated cells as a result of the existing feedback loop. Repeated cycles of induction allowed on/off modulation of transgene expression. In vitro analyses revealed that IL-1Ra protein present in the conditioned medium from MSC/IL-1Ra cells blocks OA onset in cytokine-treated equine chondrocytes and co-cultivation of MSC/IL-1Ra cells with osteoarthritic spheroids alleviates the severity of the osteoarthritic changes.Thus, pro-inflammatory cytokine induced IL-1Ra protein expression from genetically modified MSCs might represent a promising strategy for osteoarthritis treatment.© 2018 The Authors. The Journal of Gene Medicine published by John Wiley & Sons, Ltd.

Keywords Pubmed: Animals
Cells, Cultured
Chondrocytescytologymetabolism
Cytokinespharmacology
Gene Expressiondrug effects
Genetic Engineeringmethods
Genetic Therapymethods
Horse Diseasesgeneticspathologytherapy
Horses
Humans
Interleukin 1 Receptor Antagonist Proteingeneticsmetabolism
Lentivirusgenetics
Male
Mesenchymal Stem Cellscytologymetabolism
Metalloendopeptidasesgeneticsmetabolism
Osteoarthritisgeneticspathologytherapy
Tumor Necrosis Factor-alphapharmacology

© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit